Molecular Signaling Pathways behind the Biological Effects of Salvia Species Diterpenes in Neuropharmacology and Cardiology

Phytotherapy Research

Volumn 30, Issue 6, 2016, Pages 878-893

  Akaberi, M ^a   Iranshahi, M ^a   Mehri, S ^b  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

cell signaling pathway; miltirone; Salvia; salvinorin A; tanshinone

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; 7 METHOXYROSMANOL; AMYLOID BETA PROTEIN; BENZODIAZEPINE RECEPTOR; CARNOSIC ACID; CARNOSOL; CRYPTOTANSHINONE; DIHYDROTANSHINONE; DITERPENE; DIVINATORIN D; DIVINATORIN E; GALDOSOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KAPPA OPIATE RECEPTOR; MILTIRONE; MITOGEN ACTIVATED PROTEIN KINASE; PLACEBO; SALVINICIN B; SALVINORIN A; SALVINORIN G; SCLAREOL; TANSHINOATE B; TANSHINONE; TANSHINONE I; TANSHINONE IIA; TANSHINONE SULFONATE; TAU PROTEIN; TAXODIONE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ABIETANE DERIVATIVE; ANTINEOPLASTIC AGENT; BIOLOGICAL PRODUCT; PHENANTHRENE DERIVATIVE;

ANTIARRHYTHMIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; CARDIOVASCULAR DISEASE; DRUG EFFECT; DRUG STRUCTURE; ENZYME ACTIVITY; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE INJURY; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; INTESTINE INNERVATION; LIPID METABOLISM; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SALVIA; SALVIA MILTIORRHIZA; SIGNAL TRANSDUCTION; CHEMISTRY; NEUROPHARMACOLOGY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL PRODUCTS; DITERPENES; DITERPENES, ABIETANE; NEUROPHARMACOLOGY; PHENANTHRENES; SALVIA; SIGNAL TRANSDUCTION;

EID: 84961263132     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.5599     Document Type: Review

References (163)

1. Alvarez A, Toro R, Caceres A, Maccioni RB,. 1999. Inhibition of tau phosphorylating protein kinase Cdk5 prevents beta-amyloid-induced neuronal death. FEBS Lett 459: 421-426.
2. Aruoma OI, Halliwell B, Aeschbach R, Lolingers J,. 1992. Antioxidant and pro-oxidant properties of active rosemary constituents: carnosol and carnosic acid. Xenobiotica 22: 257-268.
3. Beerepoot P, Lam V, Luu A, Tsoi B, Siebert D, Szechtman H,. 2008. Effects of salvinorin A on locomotor sensitization to D2/D3 dopamine agonist quinpirole. Neurosci Lett 446: 101-104.
4. Bormann J,. 2000. The 'ABC' of GABA receptors. Trends Pharmacol Sci 21: 16-19.
5. Braida D, Limonta V, Capurro V, et al., 2008. Involvement of kappa-opioid and endocannabinoid system on salvinorin A-induced reward. Biol Psychiatry 63: 286-292.
6. Braida D, Capurro V, Zani A, et al., 2009. Potential anxiolytic- and antidepressant-like effects of salvinorin A, the main active ingredient of Salvia divinorum, in rodents. Br J Pharmacol 157: 844-853.
7. Butelman ER, Kreek MJ,. 2015. Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders. Front Pharmacol 6: 190.
8. Cao EH, Liu XQ, Wang JJ, Xu NF,. 1996. Effect of natural antioxidant tanshinone II-A on DNA damage by lipid peroxidation in liver cells. Free Radic Biol Med 20: 801-806.
9. Capasso R, Borrelli F, Capasso F, et al., 2006. The hallucinogenic herb Salvia divinorum and its active ingredient salvinorin A inhibit enteric cholinergic transmission in the guinea-pig ileum. Neurogastroenterol Motil 18: 69-75.
10. Capasso R, Borrelli F, Cascio MG, et al., 2008. Inhibitory effect of salvinorin A, from Salvia divinorum, on ileitis-induced hypermotility: cross-talk between kappa-opioid and cannabinoid CB(1) receptors. Br J Pharmacol 155: 681-689.
11. Capasso R, Borrelli F, Zjawiony J, et al., 2008. The hallucinogenic herb Salvia divinorum and its active ingredient salvinorin A reduce inflammation-induced hypermotility in mice. Neurogastroenterol Motil 20: 142-148.
12. Chan P, Liu JC, Lin LJ, et al., 2011. Tanshinone IIA inhibits angiotensin II-induced cell proliferation in rat cardiac fibroblasts. Am J Chin Med 39: 381-394.
13. Chavkin C, Sud S, Jin W, et al., 2004. Salvinorin A, an active component of the hallucinogenic sage Salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations. J Pharmacol Exp Ther 308: 1197-1203.
14. Chen TH, Hsu YT, Chen CH, Kao SH, Lee HM,. 2007. Tanshinone IIA from Salvia miltiorrhiza induces heme oxygenase-1 expression and inhibits lipopolysaccharide-induced nitric oxide expression in RAW 264.7 cells. Mitochondrion 7: 101-105.
15. Chen WY, Tang FT, Chen SR, Liu PQ,. 2008. Phylactic effect of tanshinone IIA on atherogenesis. Zhong Guo Yao Fang 19: 884-887.
16. Crews L, Masliah E,. 2010. Molecular mechanisms of neurodegeneration in Alzheimer's disease. Hum Mol Genet 19: R12-R20.
17. Çulhaoglu B, Yapara G, Dirmencic T, Topçu G,. 2013. Bioactive constituents of Salvia chrysophylla Stapf. Nat Prod Res 27: 438-447.
18. Dastmalchi K, Dorman HJD, Vuorela H, Hiltunen R,. 2007. Plants as potential sources for drug development against Alzheimer disease. Int J Biomd Pharmaceut Sci 1: 83-104.
19. David YW, Lee ZM, Lee-Yuan LC, et al., 2005. New neoclerodane diterpenoids isolated from the leaves of Salvia divinorum and their binding affinities for human k opioid receptors. Bioorg Med Chem 13: 5635-5639.
20. DeHaven-Hudkins DL, Dolle RE,. 2004. Peripherally restricted opioid agonists as novel analgesic agents. Curr Pharm Des 10: 743-757.
21. Deshpande A, Mina E, Glabe C, Busciglio J,. 2006. Different conformations of amyloid β induce neurotoxicity by distinct mechanisms inhumancorticalneurons. J Neurosci 26: 6011-6018.
22. dos Santos RG, Crippa JA, Machado-de-Sousa JP, Hallak JE,. 2014. Salvinorin a and related compounds as therapeutic drugs for psychostimulant-related disorders. Curr Drug Abuse Rev 7: 128-132.
23. Du JR, Li X, Zhang R, Qian ZM,. 2005. Tanshinone inhibits intimal hyperplasia in the ligated carotid artery in mice. J Ethnopharmacol 98: 319-322.
24. Dweck AC,. 2000. The folklore and cosmetics use of various Salvia species. In The genus Salvia, Kintzios SE, (ed). Harwood Academic Publishers: Amsterdam, the Netherlands; 1-25.
25. Faia KL, Davis WP, Marone AJ, Foxall TL,. 2002. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in hamster aortic atherosclerosis: correlation with in-situ zymography. Atherosclerosis 160: 325-337.
26. Fan GW, Gao XM, Wang H, et al., 2009. The anti-inflammatory activities of Tanshinone IIA, an active component of TCM, are mediated by estrogen receptor activation and inhibition of iNOS. J Steroid Biochem Mol Biol 113: 275-280.
27. Fang J, Xu SW, Wang P, et al., 2010. Tanshinone II-A attenuates cardiac fibrosis and modulates collagen metabolism in rats with renovascular hypertension. Phytomedicine 18: 58-64.
28. Fang ZY, Lin R, Yuan BX, Liu Y, Zhang H,. 2007. Tanshinone IIA inhibits atherosclerotic plaque formation by down-regulating MMP-2 and MMP-9 expression in rabbits fed a high-fat diet. Life Sci 81: 1339-1345.
29. Fang ZY, Lin R, Yuan BX, Yang GD, Liu Y, Zhang H,. 2008. Tanshinone IIA downregulates the CD40 expression and decreases MMP-2 activity on atherosclerosis induced by high fatty diet in rabbit. J Ethnopharmacol 115: 217-222.
30. Fichna J, Dicay M, Hirota SA, et al., 2011. Differential effects of salvinorin A on endotoxin-induced hypermotility and neurogenic ion transport in mouse ileum. Neurogastroenterol Motil 23: 583-e212.
31. Fichna J, Dicay M, Lewellyn K, et al., 2012. Salvinorin A has antiinflammatory and antinociceptive effects in experimental models of colitis in mice mediated by KOR and CB1 receptors. Inflamm Bowel Dis 18: 1137-1145.
32. Fichna J, Schicho R, Andrews CN, et al., 2009. Salvinorin A inhibits colonic transit and neurogenic ion transport in mice by activating κ-opioid and cannabinoid receptors. Neurogastroenterol Motil 21: 1326-e128.
33. Fredriksson R, Lagerstrom MC, Lundin LG, Schioth HB,. 2003. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol 63: 1256-1272.
34. Fu J, Huang H, Liu J, Pi R, Chen J, Liu P,. 2007. Tanshinone IIA protects cardiac myocytes against oxidative stress-triggered damage and apoptosis. Eur J Pharmacol 568: 213-221.
35. Galkina E, Ley K,. 2009. Immune and inflammatory mechanisms of atherosclerosis. Annu Rev Immunol 27: 165-197.
36. Gao J, Yang G, Pi R, et al., 2008. Tanshinone IIA protects neonatal rat cardiomyocytes from adriamycin-induced apoptosis. Transl Res 151: 79-87.
37. Gao S, Liu Z, Li H, Little PJ, Liu P, Xu S,. 2012. Cardiovascular actions and therapeutic potential of tanshinone IIA. Atherosclerosis 220: 3-10.
38. Gaziano TA, Bitton A, Anand S, Abrahams-Gessel S, Murphy A,. 2010. Growing epidemic of coronary heart disease in low- and middle-income countries. Curr Probl Cardiol 35: 72-115.
39. Goedert M,. 1996. Tau protein and the neurofibrillary pathology of Alzheimer's disease. Ann N Y Acad Sci 777: 121-131.
40. Goedert M,. 1998. Neurofibrillary pathology of Alzheimer's disease and other tauopathies. Prog Brain Res 117: 287-306.
41. Gong Z, Huang C, Sheng X, et al., 2009. The role of tanshinone IIA in the treatment of obesity through peroxisome proliferator-activated receptor gamma antagonism. Endocrinology 150: 104-113.
42. Harding WW, Tidgewell K, Schmidt M, et al., 2005. Salvinicins A and B, new neoclerodane diterpenes from Salvia divinorum. Org Lett 7: 3017-3020.
43. Hopkins AL, Groom CR,. 2002. The druggable genome. Nat Rev Drug Discov 1: 727-730.
44. Chan H-H, Hwang T-L, Su CR, Reddy MVB, Wu T-S,. 2011. Anti-inflammatory, anticholinesterase and antioxidative constituents from the roots and the leaves of Salvia nipponica Miq. Var formosana Phytomedicine 18: 148-150.
45. Huang KJ, Wang H, Xie WZ, Zhang HS,. 2007. Investigation of the effect of tanshinone IIA on nitric oxide production in human vascular endothelial cells by fluorescence imaging. Spectrochim Acta A Mol Biomol Spectrosc 68: 1180-1186.
46. Iriti M, Vitalini S, Fico G, Faoro F,. 2010. Neuroprotective herbs and foods from different traditional medicines and diets. Molecules 15: 3517-3555.
47. Itoh K, Tong KI, Yamamoto M,. 2004. Molecular mechanism activating Nrf2-Keap1 pathway in regulation of adaptive response to electrophiles. Free Radic Biol Med 36: 1208-1213.
48. Jang SI, Jeong SI, Kim KJ, et al., 2003. Tanshinone IIA from Salvia miltiorrhiza inhibits inducible nitric oxide synthase expression and production of TNF-alpha, IL-1beta and IL-6 in activated RAW 264.7 cells. Planta Med 69: 1057-1059.
49. Jang SI, Kim HJ, Kim YJ, Jeong SI, You YO,. 2006. Tanshinone IIA inhibits LPS-induced NF-kappaB activation in RAW 264.7 cells: possible involvement of the NIK-IKK, ERK1/2, p38 and JNK pathways. Eur J Pharmacol 542: 1-7.
50. Jiang FL, Leo S, Wang XG, et al., 2006. Effect of tanshinone IIA on myocardial cell apoptosis protein of spontaneously hypertensive rats with left ventricular hypertrophy. Chin J Clin Rehabil 10: 58-60.
51. Jiang P, Chen M, Lu J, Chen C, Jiao BH,. 2010. Effect of tanshinone II A on MMP-2 and iNOS expression and free radical release in hippocampus of rat Alzheimer's disease model. Acad J Sec Milit Med Univ 31: 380-384.
52. Jiang P, Li C, Xiang Z, Jiao B,. 2014. Tanshinone IIA reduces the risk of Alzheimer's disease by inhibiting iNOS, MMP-2 and NF-kappa Bp65 transcription and translation in the temporal lobes of rat models of Alzheimer's disease. Mol Med Rep 10: 689-694.
53. Jiang WD, Yu YZ, Liu WW, Chen YH, Wang YP, Huang TC,. 1981. Effects of sodium tanshinone II-A sulfonate and propranolol on coronary collaterals in acutely infarcted dogs. Zhongguo Yao Li Xue Bao 2: 29-33.
54. Jin UH, Suh SJ, Chang HW, et al., 2008. Tanshinone IIA from Salvia miltiorrhiza BUNGE inhibits human aortic smooth muscle cell migration and MMP-9 activity through AKT signaling pathway. J Cell Biochem 104: 15-26.
55. Johnson MW, MacLean KA, Reissig CJ, Prisinzano TE, Griffiths RR,. 2011. Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum. Drug Alcohol Depend 115: 150-155.
56. Kamatou GPP,. 2006. Indigenous Salvia species-An Investigation of their Pharmacological Activities and Phytochemistry. University of the Witwatersrand: Johannesburg.
57. Kang YJ, Jin UH, Chang HW, et al., 2008. Inhibition of microsomal triglyceride transfer protein expression and atherogenic risk factor apolipoprotein B100 secretion by tanshinone IIA in HepG2 cells. Phytother Res 22: 1640-1645.
58. Karmin O, Cheung F, Sung FL, Zhu DY, Siow YL,. 2000. Effect of magnesium tanshinoate B on the production of nitric oxide in endothelial cells. Mol Cell Biochem 207: 35-39.
59. Kavvadias D, Monschein V, Sand P, Riederer P, Schreier P,. 2003. Constituents of sage (Salvia officinalis) with in vitro affinity to human brain benzodiazepine receptor. Planta Med 69: 113-117.
60. Kesavapany S, Zheng YL, Amin N, Pant HC,. 2007. Peptides derived from Cdk5 activator p35, specifically inhibit deregulated activity of Cdk5. Biotechnol J 2: 978-987.
61. Kosaka K, Yokoi T,. 2003. Carnosic acid, a component of rosemary (Rosmarinus officinalis L.), promotes synthesis of nerve growth factor in T98g human glioblastoma cells. Biol Pharm Bull 26: 1620-1622.
62. Kroeze WK, Sheffler DJ, Roth BL,. 2003. G-protein coupled receptors at a glance. J Cell Sci 116: 4867-4869.
63. Kumar GP, Khanum F,. 2012. Neuroprotective potential of phytochemicals. Pharmacogn Rev 6: 81-90.
64. Lam FF, Yeung JH, Chan KM, Or PM,. 2008. Dihydrotanshinone, a lipophilic component of Salvia miltiorrhiza (danshen), relaxes rat coronary artery by inhibition of calcium channels. J Ethnopharmacol 119: 318-321.
65. Lander ES, Linton LM, Birren B, et al., 2001. Initial sequencing and analysis of the human genome. Nature 409: 860-921.
66. Lane RM, Potkin SG, Enz A,. 2006. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Int J Neuropsychopharmacol 9: 101-124.
67. Lee CM, Wong HN, Chui KY, Choang TF, Hon PM, Chang HM,. 1991. Miltirone, a central benzodiazepine receptor partial agonist from a Chinese medicinal herb Salvia miltiorrhiza. Neurosci Lett 127: 237-241.
68. Lee MS, Kwon YT, Li M, Peng J, Friedlander RM, Tsai LH,. 2000. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 405: 360-364.
69. Li SS, Feng J, Zheng Z, Liang QS,. 2008. Effect of sodium tanshinone II A sulfonate on phosphorylation of extracellular signal-regulated kinase 1/2 in angiotensin II-induced hypertrophy of myocardial cells. Chin J Integr Med 14: 123-127.
70. Li X, Du JR, Bo B, et al., 2008. Inhibitory effects and mechanism of tanshinone II A on proliferation of rat aortic smooth muscle cells. Zhongguo Zhongyao Zazhi 33: 2146-2150.
71. Li X, Du JR YY, Bai B, Zheng XY,. 2010. Tanshinone IIA inhibits smooth muscle proliferation and intimal hyperplasia in the rat carotid balloon-injured model through inhibition of MAPK signaling pathway. J Ethnopharmacol 129: 273-279.
72. Li Y, Yang Y, Yu D, Liang Q,. 2009. The effect of tanshinone IIA upon the TGF-beta1/SMADS signaling pathway in hypertrophic myocardium of hypertensive rats. J Huazhong Univ Sci Technolog Med Sci 29: 476-480.
73. Li YI, Elmer G, Leboeuf RC,. 2008. Tanshinone IIA reduces macrophage death induced by hydrogen peroxide by upregulating glutathione peroxidase. Life Sci 83: 557-562.
74. Li YS, Wang ZH, Wang J,. 2008a. Effect of tanshinone II A on angiotensin receptor in hypertrophic myocardium of rats with pressure over-loading. Zhongguo Zhong xi yi jie he za zhi 28: 632-636.
75. Li YS, Wang ZH, Wang J, et al., 2008b. Effect and molecular mechanism of tashinon IIA on the hypertrophic cadiocyte due to abdominal aorta stenosis in rats. Chin Pharm J 43: 1313-1316+1317.
76. Li YS, Wang ZH, Yan L, et al., 2008c. Effect of tashinone on nitric oxide synthase in hypertrophic cardiomyocyte of rats suffered abdominal aorta constriction. Zhongguo Zhong Yao Za Zhi 33: 1446-1450.
77. Ling S, Nheu L, Dai A, Guo Z, Komesaroff P,. 2008. Effects of four medicinal herbs on human vascular endothelial cells in culture. Int J Cardiol 128: 350-358.
78. Little PJ, Osman N, O'Brien KD,. 2008. Hyperelongated biglycan: the surreptitious initiator of atherosclerosis. Curr Opin Lipidol 19: 448-454.
79. Luo Y, Xu DQ, Dong HY, et al., 2013. Tanshinone IIA inhibits hypoxia-induced pulmonary artery smooth muscle cell proliferation via Akt/Skp2/ p27-associated pathway. PLoS One 8 (2): e56774.
80. Maqueda AE, Valle M, Addy PH, et al., 2015. Salvinorin-A induces intense dissociative effects, blocking external sensory perception and modulating interoception and sense of body ownership in humans. Int J Neuropsychopharmacol 8 (12): pii: pyv065.
81. Martin D, Rojo AI, Salinas M, et al., 2004. Regulation of heme oxygenase-1 expression through the phosphatidylinositol 3-kinase/Akt pathway and the Nrf2 transcription factor in response to the antioxidant phytochemical carnosol. J Biol Chem 279: 8919-8929.
82. Matrisian LM,. 1990. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 6: 121-125.
83. McGraw LK, Turner BS, Stotts NA, Dracup KA,. 2008. A review of cardiovascular risk factors in US military personnel. J Cardiovasc Nurs 23: 338-344.
84. Mei Z, Situ B, Tan X, et al., 2010. Cryptotanshinione upregulates α-secretase by activation PI3K pathway in cortical neurons. Brain Res 1348: 165-173.
85. Mostallino MC, Mascia MP, Pisu MG, Busonero F, Talani G, Biggio G,. 2004. Inhibition by miltirone of up-regulation of GABAA receptor α4 subunit mRNA by ethanol withdrawal in hippocampal neurons. Eur J Pharmacol 494: 83-90.
86. Motwani JG, Topol EJ,. 1998. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation 97: 916-931.
87. Murphy JE, Tedbury PR, Homer-Vanniasinkam S, Walker JH, Ponnambalam S,. 2005. Biochemistry and cell biology of mammalian scavenger receptors. Atherosclerosis 182: 1-15.
88. Niu XL, Ichimori K, Yang X, et al., 2000. Tanshinone II-A inhibits low density lipoprotein oxidation in vitro. Free Radic Res 33: 305-312.
89. Obregon DF, Rezai-Zadeh K, Bai Y, et al., 2006. ADAM10 activation is required for green tea(-)-epigallocatechin-3-gallate-induced alpha-secretase cleavage of amyloid precursor protein. J Biol Chem 281: 16419-16427.
90. Ortega A, Blount JF, Manchand PS,. 1982. Salvinorin, a new trans-neoclerodane diterpene from Salvia divinorum (Labiatae). J Chem Soc 1: 2505-2508.
91. Pan YJ, Li XY, Yang GT,. 2009. Effect of tanshinone II A on the calcineurin activity in proliferating vascular smooth muscle cells of rats. Zhongguo Zhong Xi Yi Jie He Za Zhi 29: 133-135.
92. Park JH, Park OK, Cho JH, et al., 2014. Anti-inflammatory effect of tanshinone I in neuroprotection against cerebral ischemia-reperfusion injury in the gerbil hippocampus. Neurochem Res 39: 1300-1312.
93. Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH,. 1999. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402: 615-622.
94. Pfeiffer A, Brantl V, Herz A, Emrich HM,. 1986. Psychotomimesis mediated by kappa opiate receptors. Science 233: 774-776.
95. Pleckaityte M,. 2010. Alzheimer's disease: a molecular mechanism, new hypotheses, and therapeutic strategies. Medicina 46: 70-76.
96. Qian YH, Xiao Q, Xu J,. 2012. The protective effects of tanshinone IIA on β-amyloid protein (1-42)-induced cytotoxicity via activation of the Bcl-xL pathway in neuron. Brain Res Bull 88: 354-358.
97. Ranganathan M, Schnakenberg A, Skosnik PD, et al., 2012. Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the kappa opioid agonist Salvinorin A in humans. Biol Psychiatry 72: 871-879.
98. Rau O, Wurglics M, Paulke A, et al., 2006. Carnosic acid and carnosol, phenolic diterpene compounds of the labiate herbs rosemary and sage, are activators of the human peroxisome proliferator-activated receptor gamma. Planta Med 72: 881-887.
99. Reichman WE,. 2003. Current pharmacologic options for patients with Alzheimer's disease. Ann Gen Hosp Psychiatry 2: 1.
100. Ren Y, Houghton PJ, Hider RC, Howes MJR,. 2004. Novel diterpenoid acetylcholinesterase inhibitors from Salvia miltiorhiza. Planta Med 70: 201-204.
101. Ren ZH, Tong YH, Xu W, Ma J, Chen Y,. 2010. Tanshinone II A attenuates inflammatory responses of rats with myocardial infarction by reducing MCP-1 expression. Phytomedicine 17: 212-218.
102. Rimoy GH, Wright DM, Bhaskar NK, Rubin PC,. 1994. The cardiovascular and central nervous system effects in the human of U-62066E. A selective opioid receptor agonist. Eur Clin Pharmacol 46: 203-207.
103. Ross R,. 1993. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362: 801-809.
104. Roth BL, Baner K, Westkaemper R, et al., 2002. Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci U S A 99: 11934-11939.
105. Roth BL, Lopez E, Beischel S, Westkaemper RB, Evans JM,. 2004. Screening the receptorome to discover the molecular targets for plant-derived psychoactive compounds: a novel approach for CNS drug discovery. Pharmacol Ther 102: 99-110.
106. Roth BL, Willins DL, Kristiansen K, Kroeze WK,. 1998. 5-hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): where structure meets function. Pharmacol Ther 79: 231-257.
107. Rutherford DM, Nielsen MP, Hansen SK, Witt MR, Bergendorff O, Sterner O,. 1992. Isolation and identification from Salvia officinalis of two diterpenes which inhibit t-butylbicyclophosphoro[35S]thionate binding to chloride channel of rat cerebrocortical membranes in vitro. Neurosci Lett 135: 224-226.
108. Sasaguri Y, Murahashi N, Sugama K, et al., 1994. Development-related changes in matrix metalloproteinase expression in human aortic smooth muscle cells. Lab Invest 71: 261-269.
109. Satoh T, Lipton SA,. 2007. Redox regulation of neuronal survival mediated by electrophilic compounds. Trends Neurosci 30: 37-45.
110. Satoh T, Izumi M, Inukai Y, et al., 2008. Carnosic acid protects neuronal HT22 Cells through activation of the antioxidant-responsive element in free carboxylic acid- and catechol hydroxyl moieties-dependent manners. Neurosci Lett 434: 260-265.
111. Satoh T, Kosaka K, Itoh K, et al., 2008. Carnosic acid, a catechol-type electrophilic compound, protects neurons both in vitro and in vivo through activation of the Keap1/Nrf2 pathway via S-alkylation of targeted cysteines on Keap1. J Neurochem 104: 1116-1131.
112. Satoh T, Okamoto SI, Cui J, et al., 2006. Activation of the Keap1/Nrf2 pathway for neuroprotection by electrophilic phase II inducers. Proc Natl Acad Sci U S A 103: 768-773.
113. Satoi H, Tomimoto H, Ohtani R, et al., 2005. Astroglial expression of ceramide in Alzheimer's disease brains: a role during neuronal apoptosis. Neuroscience 130: 657-666.
114. Schwartz SM, deBlois D, O'Brien ER,. 1995. The intima. Soil for atherosclerosis and restenosis. Circ Res 77: 445-465.
115. Selkoe DJ,. 1999. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 399: A23-A31.
116. Shan H, Li X, Pan Z, et al., 2009. Tanshinone IIA protects against sudden cardiac death induced by lethal arrhythmias via repression of microRNA-1. Br J Pharmacol 168: 1227-1235.
117. Sheffler DJ, Roth BL,. 2003. Salvinorin A: the "magic mint" hallucinogen finds a molecular target in the kappa opioid receptor. Trends Pharmacol Sci 24: 107-109.
118. Shi LL, Yang WN, Chen XL, et al., 2012. The protective effects of tanshinone IIA on neurotoxicity induced by β-amyloid protein through calpain and the p35/Cdk5 pathway in primary cortical neurons. Neurochem Int 61: 227-235.
119. Siebert DJ,. 1994. Salvia divinorum and salvinorin A: new pharmacologic findings. J Ethnopharmacol 43: 53-56.
120. Smith JP, Lal V, Bowser D, Cappai R, Masters CL, Ciccotosto GD,. 2009. Stimulus pattern dependence of the Alzheimer's disease amyloid-beta 42 peptide's inhibition of long term potentiation in mouse hippocampal slices. Brain Res 7: 176-184.
121. Su JH, Anderson AJ, Cummings BJ, Cotman CW,. 1994. Immunohistochemical evidence for apoptosis in Alzheimer's disease. Neuroreport 5: 2529-2533.
122. Suh SJ, Jin UH, Choi HJ, et al., 2006. Cryptotanshinone from Salvia miltiorrhiza BUNGE has an inhibitory effect on TNF-α-induced matrix metalloproteinase-9 production and HASMC migration via down-regulated NF-κB and AP-1. Biochem Pharmacol 72: 1680-1689.
123. Sun DD, Wang HC, Wang XB, et al., 2008. Tanshinone IIA: a new activator of human cardiac KCNQ1/KCNE1 (I(Ks)) potassium channels. Eur J Pharmacol 590: 317-321.
124. Takahashi K, Ouyang X, Komatsu K, et al., 2002. Sodium tanshinone IIA sulfonate derived from Danshen (Salvia miltiorrhiza) attenuates hypertrophy induced by angiotensin II in cultured neonatal rat cardiac cells. Biochem Pharmacol 64: 745-749.
125. Talalay P,. 2000. Chemoprotection against cancer by induction of phase 2 enzymes. Biofactors 12: 5-11.
126. Tan X, Li J, Wang X, et al., 2011. Tanshinone IIA protects against cardiac hypertrophy via inhibiting calcineurin/Nfatc3 pathway. Int J Biol Sci 7: 383-389.
127. Tang F, Wu X, Wang T, et al., 2007. Tanshinone II A attenuates atherosclerotic calcification in rat model by inhibition of oxidative stress. Vascul Pharmacol 46: 427-438.
128. Tang FT, Cao Y, Wang TQ, et al., 2011. Tanshinone IIA attenuates atherosclerosis in ApoE(-/-) mice through down-regulation of scavenger receptor expression. Eur J Pharmacol 650: 275-284.
129. Tu EY, Zhou YG, Wang ZH, Liang QS, Yang GT,. 2009. Effects of tanshinone II A on the myocardial hypertrophy signal transduction system protein kinase B in rats. Chin J Integr Med 15: 365-370.
130. Valdes LJ, Butler WM, Hatfield GM, Paul AG, Koreeda M,. 1984. Divinorin-A, a psychotropic terpenoid, and divinorin-B from the hallucinogenic Mexican mint Salvia divinorum. J Org Chem 49: 4716-4720.
131. Vassar R,. 2005. beta-Secretase, APP and Abeta in Alzheimer's disease. Subcell Biochem 38: 79-103.
132. Vassilatis DK, Hohmann JG, Zeng H, et al., 2003. The G-protein coupled receptor repertoires of human and mouse. Proc Natl Acad Sci U S A 100: 4903-4908.
133. Walsh SL, Strain EC, Abreu ME, Bigelow GE,. 2001. Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology (Berl) 157: 151-162.
134. Wang H, Gao XM, Zhang BL, Chai LJ, Hu LM, Wang SX,. 2005. Effects of tanshinon on VSMC proliferation and the expression of pp-ERK1/2 protein in rats. Chin Pharm J 40: 106-108.
135. Wang ZH, Liang QS, Zheng Z,. 2006. The effect of tanshinone on L-type calcium current in hypertrophic myocardium. Chin J Hypertens 14: 450-454.
136. Wang Z, Ma N, Riley J, Armstead WM, Liu R,. 2012. Salvinorin a administration after global cerebral hypoxia/ischemia preserves cerebrovascular autoregulation via kappa opioid receptor in piglets. PLoS One 7 (7): e41724.
137. Wei B, You MG, Ling JJ, et al., 2013. Regulation of antioxidant system, lipids and fatty acid beta-oxidation contributes to the cardioprotective effect of sodium tanshinone IIA sulphonate in isoproterenol-induced myocardial infarction in rats. Atherosclerosis 230: 148-156.
138. Wong KK, Ho MT, Lin HQ, et al., 2010. Cryptotanshinone, an acetylcholinesterase inhibitor from Salvia miltiorrhiza, ameliorates scopolamine-induced amnesia in Morris water maze task. Planta Med 76: 228-234.
139. Wong KKK, Ngo JCK, Liu S, et al., 2010. Interaction study of two diterpenes, cryptotanshinone and dihydrotanshinone, to human acetylcholinesterase and butyrylcholinesterase by molecular docking and kinetic analysis. Chem Biol Interact 187: 335-339.
140. Wu YB, Ni ZY, Shi QW, et al., 2012. Constituents from Salvia species and their biological activities. Chem Rev 112: 5967-6026.
141. Wu GB, Zhou EX, Qing DX,. 2009. Tanshinone II(A) elicited vasodilation in rat coronary arteriole: roles of nitric oxide and potassium channels. Eur J Pharmacol 617: 102-107.
142. Wu TW, Zeng LH, Fung KP,. 1993. Effect of sodium tanshinone IIA sulfonate in the rabbit myocardium and on human cardiomyocytes and vascular endothelial cells. Biochem Pharmacol 12: 2327-2332.
143. Xu CQ, Lou YP, Yang BF,. 1998. Correlation analysis of tanshinone IIA's inhibition of L-type calcium current and its shortening of action potential duration in cardiomyocytes of guinea pig. Chin Pharmacol Bull 14: 428-431.
144. Xu S, Little PJ, Lan T, et al., 2011. Tanshinone II-A attenuates and stabilizes atherosclerotic plaques in apolipoprotein-E knockout mice fed a high cholesterol diet. Arch Biochem Biophys 515: 72-79.
145. Xu S, Liu Z, Huang Y, et al., 2012. Tanshinone II-A inhibits oxidized LDL-induced LOX-1 expression in macrophages by reducing intracellular superoxide radical generation and NF-kappaB activation. Transl Res 160: 114-124.
146. Xu W, Yang J, Wu LM,. 2009. Cardioprotective effects of tanshinone IIA on myocardial ischemia injury in rats. Pharmazie 64: 332-336.
147. Yagami T, Ueda K, Asakura K, et al., 2002. Gas6 rescues cortical neurons from amyloid beta protein-induced apoptosis. Neuropharmacology 43: 1289-1296.
148. Yagi A, Fujimoto K, Tanonaka K, Hirai K, Takeo S,. 1989. Possible active components of tan-shen (Salvia miltiorrhiza) for protection of the myocardium against ischemia-induced derangements. Planta Med 55: 51-54.
149. Yan F, Roth BL,. 2004. Salvinorin A: a novel and highly selective κ-opioid receptor agonist. Life Sci 75: 2615-2619.
150. Yan L, Li YS, Liang QS, Yang GT,. 2010. Effects of sodium tanshinone IIA sulfonate on myocardial hypertrophy angiotensins receptor and STAT3 of rats. Chin Trad Herb Drug 41: 588-592.
151. Yang L, Zou X, Liang Q, et al., 2007. Sodium tanshinone IIA sulfonate depresses angiotensin II-induced cardiomyocyte hypertrophy through MEK/ERK pathway. Exp Mol Med 39: 65-73.
152. Yang L, Zou XJ, Gao X, et al., 2009. Sodium tanshinone IIA sulfonate attenuates angiotensin II-induced collagen type I expression in cardiac fibroblasts in vitro. Exp Mol Med 41: 508-516.
153. Yang R, Liu A, Ma X, Li L, Su D, Liu J,. 2008. Sodium tanshinone IIA sulfonate protects cardiomyocytes against oxidative stress-mediated apoptosis through inhibiting JNK activation. J Cardiovasc Pharmacol 51: 396-401.
154. Yang Y, Cai F, Li PY, et al., 2008. Activation of high conductance Ca2 + -activated K+ channels by sodium tanshinone II-A sulfonate (DS-201) in porcine coronary artery smooth muscle cells. Eur J Pharmacol 598: 9-15.
155. Yin Y, Huang L, Liu Y, et al., 2008. Effect of tanshinone on the levels of nitric oxide synthase and acetylcholinesterase in the brain of Alzheimer's disease rat model. Clin Invest Med 31: E248-E257.
156. Zhang HS, Wang SQ,. 2007. Nrf2 is involved in the effect of tanshinone IIA on intracellular redox status in human aortic smooth muscle cells. Biochem Pharmacol 73: 1358-1366.
157. Zhang SZ, Ye ZG, Xia Q, Zhang W, Bruce I,. 2005. Inhibition of mitochondrial permeability transition pore: a possible mechanism for cardioprotection conferred by pretreatment with tanshinone IIA. Conf Proc IEEE Eng Med Biol Soc 3: 2276-2279.
158. Zhang Y, Wei L, Sun D, et al., 2010. Tanshinone IIA pretreatment protects myocardium against ischaemia/reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway in diabetic rats. Diabetes Obes Metab 12: 316-322.
159. Zhao N, Liu YY, Wang F, et al., 2010. Cardiotonic pills, a compound Chinese medicine, protects ischemia-reperfusion-induced microcirculatory disturbance and myocardial damage in rats. Am J Physiol Heart Circ Physiol 298: H1166-H1176.
160. Zhou DX, Liang QS, He XX, Zhan CY,. 2008. Changes of c-fos, c-jun mRNA expressions in cardiomyocyte hypertrophy induced by angiotensin II and effects of tanshinone II A. Zhongguo Zhong Yao Za Zhi 33: 936-939.
161. Zhou G, Jiang W, Zhao Y, et al., 2003. Sodium tanshinone IIA sulfonate mediates electron transfer reaction in rat heart mitochondria. Biochem Pharmacol 65: 51-57.
162. Zhou GY, Zhao BL, Hou JW, Ma GE, Xin WJ,. 1999. Protective effects of sodium tanshinone IIA sulphonate against adriamycin-induced lipid peroxidation in mice hearts in vivo and in vitro. Pharmacol Res 40: 487-491.
163. Zhou Y, Li W, Xu L, Chen L,. 2011. In Salvia miltiorrhiza, phenolic acids possess protective properties against amyloid beta-induced cytotoxicity, and tanshinones act as acetylcholinesterase inhibitors. Environ Toxicol Pharmacol 31: 443-452.